<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药事纵横 | wechat-feeds</title><link>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</link><description>药事纵横是一个由多位制药精英联合创办的媒体平台，旨在分享与传递药品研发、生产和注册中所涉及的技术、经验和情报，欢迎关注和投稿！投稿请发442015666@qq.com</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 05 Mar 2021 11:36:12 +0800</pubDate><image><url>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</url><title>药事纵横 | wechat-feeds</title><link>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>浅谈药物晶型</title><link>https://mp.weixin.qq.com/s/moonB6OA6Akqjrmp4ULnzA</link><description></description><content:encoded><![CDATA[浅谈药物晶型]]></content:encoded><pubDate>Fri, 05 Mar 2021 08:34:05 +0800</pubDate></item><item><title>细说高效液相色谱模块使用注意事项</title><link>https://mp.weixin.qq.com/s/IlYda4Wv4swdsgmb30stTw</link><description></description><content:encoded><![CDATA[细说高效液相色谱模块使用注意事项]]></content:encoded><pubDate>Fri, 05 Mar 2021 08:34:05 +0800</pubDate></item><item><title>药事纵横广告投放须知</title><link>https://mp.weixin.qq.com/s/XDzGBLvb3Q0p8-upua2cXg</link><description></description><content:encoded><![CDATA[药事纵横广告投放须知]]></content:encoded><pubDate>Fri, 05 Mar 2021 08:34:05 +0800</pubDate></item><item><title>探究创新药物理化性质的底层逻辑</title><link>https://mp.weixin.qq.com/s/wDJtnsLsXhpJ-p904HS4lw</link><description></description><content:encoded><![CDATA[探究创新药物理化性质的底层逻辑]]></content:encoded><pubDate>Thu, 04 Mar 2021 09:34:16 +0800</pubDate></item><item><title>液相方法开发指南-反相色谱</title><link>https://mp.weixin.qq.com/s/iKJ20Q_0UW5zukPd9ykc6A</link><description></description><content:encoded><![CDATA[液相方法开发指南-反相色谱]]></content:encoded><pubDate>Thu, 04 Mar 2021 09:34:16 +0800</pubDate></item><item><title>药事纵横投稿须知</title><link>https://mp.weixin.qq.com/s/nWi5-iljnfRJbj4S8CFQXQ</link><description></description><content:encoded><![CDATA[药事纵横投稿须知]]></content:encoded><pubDate>Thu, 04 Mar 2021 09:34:16 +0800</pubDate></item><item><title>基于PLGA用于缓释微粒的制备方法及提高载药量的策略</title><link>https://mp.weixin.qq.com/s/jGMlGhurpvuVqIzya1KVjQ</link><description></description><content:encoded><![CDATA[基于PLGA用于缓释微粒的制备方法及提高载药量的策略]]></content:encoded><pubDate>Wed, 03 Mar 2021 08:20:52 +0800</pubDate></item><item><title>​寻找中国生物医药投资的圣杯</title><link>https://mp.weixin.qq.com/s/FCZwIBn-dpA0R4N3hZAscA</link><description></description><content:encoded><![CDATA[​寻找中国生物医药投资的圣杯]]></content:encoded><pubDate>Wed, 03 Mar 2021 08:20:52 +0800</pubDate></item><item><title>粉末直压工艺研究要点与粉体学性质表征重要性</title><link>https://mp.weixin.qq.com/s/rXBQrWeWe_C4JQMnqeyjtg</link><description></description><content:encoded><![CDATA[粉末直压工艺研究要点与粉体学性质表征重要性]]></content:encoded><pubDate>Tue, 02 Mar 2021 08:00:47 +0800</pubDate></item><item><title>【不容错过】2021药品研发分析和QC实验室合规并如何从困惑走向卓越</title><link>https://mp.weixin.qq.com/s/R_6FJElQAt2lesqZYXES4A</link><description></description><content:encoded><![CDATA[【不容错过】2021药品研发分析和QC实验室合规并如何从困惑走向卓越]]></content:encoded><pubDate>Tue, 02 Mar 2021 08:00:47 +0800</pubDate></item><item><title>浅谈色谱积分方法</title><link>https://mp.weixin.qq.com/s/ogPIc7es3cQaSeiW5XlEtw</link><description></description><content:encoded><![CDATA[浅谈色谱积分方法]]></content:encoded><pubDate>Tue, 02 Mar 2021 08:00:47 +0800</pubDate></item><item><title>雅培/艾伯维发家史：在鼎盛时分家，到底是对还是错？</title><link>https://mp.weixin.qq.com/s/Vf6kOrOItfs63IjhFG5uRQ</link><description></description><content:encoded><![CDATA[雅培/艾伯维发家史：在鼎盛时分家，到底是对还是错？]]></content:encoded><pubDate>Mon, 01 Mar 2021 09:23:02 +0800</pubDate></item><item><title>是否参会均可集赞领奖｜药品注册现场核查及M4注册申报文件撰写与递交专题培训</title><link>https://mp.weixin.qq.com/s/pCDRii-JM8pw4ccXboKDzA</link><description></description><content:encoded><![CDATA[是否参会均可集赞领奖｜药品注册现场核查及M4注册申报文件撰写与递交专题培训]]></content:encoded><pubDate>Mon, 01 Mar 2021 09:23:02 +0800</pubDate></item><item><title>关于单克隆抗体药物的10个答疑解惑</title><link>https://mp.weixin.qq.com/s/BTtOV7HfiehyOVp7Has5CA</link><description></description><content:encoded><![CDATA[关于单克隆抗体药物的10个答疑解惑]]></content:encoded><pubDate>Mon, 01 Mar 2021 09:23:02 +0800</pubDate></item><item><title>关于固体制剂处方开发中填充剂乳糖-微晶纤维素的选择思考</title><link>https://mp.weixin.qq.com/s/d0bhTY6C2zUac28rhhBvmA</link><description></description><content:encoded><![CDATA[关于固体制剂处方开发中填充剂乳糖-微晶纤维素的选择思考]]></content:encoded><pubDate>Thu, 25 Feb 2021 20:21:07 +0800</pubDate></item><item><title>色谱柱填料颗粒简介</title><link>https://mp.weixin.qq.com/s/j4sqMR12RvLYgwOse-rWwA</link><description></description><content:encoded><![CDATA[色谱柱填料颗粒简介]]></content:encoded><pubDate>Thu, 25 Feb 2021 20:21:07 +0800</pubDate></item><item><title>药事纵横广告投放须知</title><link>https://mp.weixin.qq.com/s/ryZOnvyhVx4wuZbNOTkSBQ</link><description></description><content:encoded><![CDATA[药事纵横广告投放须知]]></content:encoded><pubDate>Thu, 25 Feb 2021 20:21:07 +0800</pubDate></item><item><title>指南翻译┋生理药动学PBPK分析在生物药剂学的应用 ——口服药物的开发，工艺变更，质量控制</title><link>https://mp.weixin.qq.com/s/YwHbh9ruxvuYbNUbIY3jTg</link><description></description><content:encoded><![CDATA[指南翻译┋生理药动学PBPK分析在生物药剂学的应用 ——口服药物的开发，工艺变更，质量控制]]></content:encoded><pubDate>Wed, 24 Feb 2021 23:04:42 +0800</pubDate></item><item><title>【网络研讨会】权威剖析FDA罕见病药物开发指导原则</title><link>https://mp.weixin.qq.com/s/CyRISPtS_QTkeJcljjTYYg</link><description></description><content:encoded><![CDATA[【网络研讨会】权威剖析FDA罕见病药物开发指导原则]]></content:encoded><pubDate>Wed, 24 Feb 2021 23:04:42 +0800</pubDate></item><item><title>中药注射剂，大势已去？</title><link>https://mp.weixin.qq.com/s/Lzv9QHMV_cEERV5eOCTN2w</link><description></description><content:encoded><![CDATA[中药注射剂，大势已去？]]></content:encoded><pubDate>Wed, 24 Feb 2021 23:04:42 +0800</pubDate></item></channel></rss>